New Standards of Care in ALK-Translocated Advanced NSCLC

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Progression After Cancer Immunotherapy in Advanced NSCLC

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Optimizing Management of Advanced Bladder Cancer

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

How to Select Therapy In Newly Diagnosed CLL

Advancing Care Across the Spectrum of Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Parkinson Disease Psychosis

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

Chronic Myeloid Leukemia Challenge

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Evaluating BTK Inhibitors in CLL

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Educational Objectives

The Psychiatrist's Role in Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

New Standards of Care in ALK-Translocated Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Information Needed in Advanced NSCLC

Genetic Testing Techniques

ALK Translocations

A Newly Diagnosed Patient Case

Summary of Recent Clinical Trials

Ongoing Front-Line Clinical Trials

Faculty Experience With Alectinib Toxicities

Faculty Experience With Ceritinib Toxicities

Faculty Experience With Brigatinib Toxicities

Faculty Experience With Lorlatinib Toxicities

A Patient Who Received First-Line Crizotinib

Summary of Trials in Crizotinib-Refractory ALK-Positive NSCLC

A Patient Who Received Front-Line Alectinib

A Role for Immunotherapy?

IMPower150

Faculty Treatment Recommendations

Abbreviations

Abbreviations (cont)